Strattera is the brand name for atomoxetine, a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. It is different from commonly prescribed stimulant medicines, both in how it works and in how it is regulated.
For people comparing ADHD treatment options, the main points to know are that Strattera is a non-stimulant medication, it belongs to the selective norepinephrine reuptake inhibitor class, and it is not classified as a controlled substance under U.S. federal law. Treatment decisions should always be made with a qualified healthcare professional.
How Strattera works
Strattera contains atomoxetine, which selectively inhibits the reuptake of norepinephrine in the brain. This increases the availability of norepinephrine, a chemical involved in attention, impulse control, and executive functioning.
Unlike stimulant medications such as methylphenidate- or amphetamine-based treatments, atomoxetine does not work by providing a stimulant effect. Its benefits may develop more gradually, and some people may need several weeks before the full response becomes clear. A prescriber adjusts the treatment plan according to the individual’s response, tolerability, and medical history.
What drug class is Strattera?
Strattera is classified as a selective norepinephrine reuptake inhibitor, often abbreviated as NRI. It is not an amphetamine, methylphenidate derivative, or other stimulant medication.
This distinction helps explain why atomoxetine may be considered when a person does not tolerate stimulant treatment, has not benefited sufficiently from it, or needs a non-stimulant approach. The medication’s classification also shapes the side effects and treatment expectations that a clinician discusses with the patient.
Is Strattera a stimulant or controlled substance?
No. Strattera is not a stimulant. It does not act like amphetamines or methylphenidate and does not produce the same type of activating effect associated with those medicines.
Under U.S. federal law, atomoxetine is not a controlled substance or scheduled medication. It is still a prescription drug and should only be used under the direction of a healthcare provider. Regulations can differ outside the United States, so patients should consult a local pharmacist or prescriber about requirements in their country.
Potential side effects and safety monitoring
Although Strattera is not a stimulant, it can still cause side effects. Possible effects include:
- Stomach or gastrointestinal discomfort
- Changes in sleep
- Changes in mood or behavior
- Increased heart rate or blood pressure in some people
Rare cases of suicidal thoughts have been reported in children and adolescents taking atomoxetine. Parents, caregivers, and patients should promptly report concerning changes in mood, behavior, or thinking to the prescribing healthcare professional. A clinician may also consider cardiovascular history and monitor heart rate or blood pressure when appropriate.
People should not stop, restart, or change the dose of Strattera without medical guidance. A prescriber can explain what to do if side effects occur or if the medication does not appear to be helping.
Who might be considered for atomoxetine treatment?
A healthcare professional may consider Strattera for someone who needs a non-stimulant ADHD treatment. It may be discussed when stimulant medicines have caused difficult side effects, have not provided adequate benefit, or are a poor fit because of a person’s medical history or concerns about misuse.
Some patients and families also prefer a treatment that does not have the same immediately activating profile as stimulant medication. However, a non-stimulant option is not automatically the best choice for everyone. The decision depends on factors such as previous treatment response, coexisting conditions, cardiovascular considerations, personal preferences, and the goals of treatment.
What to discuss with a prescriber
Before starting Strattera, patients can ask how long improvement may take, which symptoms or daily activities will be monitored, and how follow-up will be handled. It is also useful to discuss:
- Previous ADHD medications and any side effects
- Other prescription medicines and health conditions
- Mood or behavioral changes that should be reported
- Changes in attention, impulsivity, school performance, work, or daily functioning
- Practical issues such as dosing routines and insurance coverage
In summary, Strattera is atomoxetine, a prescription non-stimulant ADHD medication in the selective norepinephrine reuptake inhibitor class. It is not a stimulant and is not a controlled substance under U.S. federal law. Because its effects and risks differ from those of stimulant treatments, choosing it requires an individualized discussion with a healthcare professional.
Dr. Jonathon Preston is a respected mental health specialist dedicated to helping individuals overcome challenges. With advanced training in psychology and decades of experience in the mental health field.